DxTerity Diagnostics names new chief commercialization officer
5 February 2020 -

It was reported on Tuesday, that DxTerity Diagnostics Inc, a molecular information and diagnostics company, has named Brett Swansiger as its new chief commercialization officer (CCO).

Swansiger will be responsible for identifying, developing, and negotiating strategic business collaborations with life-science organizations and establishing government and commercial payer contracts for DxTerity testing. Swansiger has experience managing care contracting in the molecular diagnostics and pharmaceutical industries. Prior to joining DxTerity, he held commercial leadership positions at MDxHealth Inc including VP of Managed Care and Payer Strategy, SVP International Business Development & European Sales, and SVP of US Sales & Integrated Healthcare Systems.

Swasniger was earlier vice president of Managed Care and Asia Market Access at Agendia Inc and held a number of commercial leadership roles at Prometheus Laboratories Inc.